A Phase 2, Double-Blind, Placebo-Controlled and Open-Label Multi-Center Study to Evaluate the Microbiology and Safety of C16G2 Administered in Multiple Oral Gel Doses to Adult and Adolescent Dental Subjects
Latest Information Update: 26 Jul 2019
At a glance
- Drugs C 16G2 (Primary)
- Indications Dental caries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Armata Pharmaceuticals; C3J Therapeutics
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 18 Mar 2016 Planned number of patients changed from 145 to 128 as per ClinicalTrials.gov record.
- 18 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.